CAR-NK Cell: A New Paradigm in Tumor Immunotherapy

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Tumor microenvironment (TME) complexity and immune escape are key drivers of tumor progression and metastasis.
• Limitations in T cell immunotherapy highlight the need for alternative immune-based strategies.
• Natural killer (NK) cells are potent innate immune effectors against tumors, exhibiting heterogeneity within the TME.

Purpose of the Study:

• To review recent advancements in the therapeutic potential of chimeric antigen receptor (CAR)-engineered NK cells for treating solid tumors.
• To summarize current challenges impacting the clinical success of CAR-NK cell immunotherapies.

Main Methods:

• Review of current scientific literature and research on CAR-NK cell therapy.
• Analysis of CAR-NK cell mechanisms, advantages over CAR-T cells, and therapeutic applications in solid tumors.
• Identification and summary of existing hurdles in CAR-NK cell-based tumor immunotherapy.

Main Results:

• CAR-NK cells offer potential advantages over CAR-T cells, including enhanced safety (minimal cytokine release syndrome and graft-versus-host disease) and 'off-the-shelf' manufacturing feasibility.
• CAR-NK cells can be engineered to target specific antigens, enhance anti-tumor activity, improve tumor infiltration, and overcome resistant TME.
• CAR-NK cells function as antigen receptors against tumor-associated antigens (TAAs), supporting immunosurveillance and anti-tumor responses.

Conclusions:

• CAR-NK cells represent a promising innovative immunotherapeutic approach for solid tumors.
• Further research is needed to address current challenges and optimize CAR-NK cell therapy for improved patient outcomes.
• CAR-NK cell technology holds significant potential for advancing cancer immunotherapy.